- Home
- ADAG vs CGEN Comparison
ADAG vs CGEN Comparison
Compare ADAG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | CGEN |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 148.7M |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ADAG | CGEN |
|---|---|---|
| Price | $3.60 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 211.2K | ★ 322.4K |
| Earning Date | 03-24-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,688.61 | N/A |
| Revenue Next Year | $17.39 | $112.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.13 |
| 52 Week High | $4.58 | $2.38 |
Technical Indicators
Market Signals| Indicator | ADAG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 52.23 |
| Support Level | $1.69 | $1.43 |
| Resistance Level | $4.58 | $2.35 |
| Average True Range (ATR) | 0.43 | 0.13 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 42.72 | 27.03 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.